Association of high PM$_{2.5}$ levels with short-term and medium-term lung function recovery in patients with pulmonary lobectomy

Yi-tong Liu$^{2,3,4,1}$, Yi Xiao$^{5,1}$, Jian Huang$^{11}$, Hao Hu$^{6}$, Xina Wang$^{3,4}$, Yueming Chen$^{2,3,4}$, Zhiqing Huang$^{2,3,4}$ and Xiongwen Yang$^{7,1,*}$

$^1$Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, China, $^2$School of Ecological Engineering, Guangdong Eco-Engineering Polytechnic, Guangzhou, China, $^3$Guangdong Collaborative Innovation Center of Plant Pest Control and Biological Environmental Health Application Technology, Guangzhou, China, $^4$Guangdong Collaborative Innovation Center of Surveying and Mapping Geographic Information and Forestry Survey Planning, Guangzhou, China, $^5$Department of Cardio-Thoracic Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, $^6$Department of Radiation Therapy, General Hospital of Southern Theater Command, Guangzhou, China, $^7$School of Medicine, South China University of Technology, Guangzhou, China

The association between exposure to ambient fine particulate matter with an aerodynamic diameter of ≤ 2.5 µm (PM$_{2.5}$) and short- and medium-term lung function recovery (LFR) in patients undergoing lobectomy remains uncertain. This study investigated the associations between PM$_{2.5}$ concentrations and LFR in adult patients ($n = 526$) who underwent video-assisted thoracoscopic (VATS) lobectomy in Guangzhou, China between January 2018 and June 2021. All patients underwent at least two spirometry tests. Environmental PM$_{2.5}$ concentrations in the same period were collected from the nearest monitoring station. A multiple linear regression (MLR) model was employed to investigate the associations between changes in PM$_{2.5}$ concentrations and LFR in patients who underwent lobectomy after adjusting for potential confounders. We assessed short- and medium-term LFR in patients who underwent lobectomy. The three- and 6-month average PM$_{2.5}$ concentrations in each patient’s residential area were divided into regional mild pollution (PM$_{2.5}$ < 25 µg/m$^3$), moderate pollution (25 µg/m$^3$ ≤ PM$_{2.5}$ < 35 µg/m$^3$), and severe pollution (35 µg/m$^3$ ≤ PM$_{2.5}$) periods. The MLR model confirmed that PM$_{2.5}$ was an independent risk factor affecting short-term forced lung capacity (FVC), forced expiratory volume in 1 s (FEV1), and maximum expiratory flow at 50% vital capacity (MEF$_{50}$) recovery (adjusted $P = 0.041$, 0.014, 0.016, respectively). The MLR model confirmed that PM$_{2.5}$ was an independent risk factor affecting medium-term MEF$_{50}$ recovery (adjusted $P = 0.046$). Compared with the moderate and severe pollution periods, the short- and medium-term LFR (FVC, FEV1, MEF$_{50}$) of patients in the mild pollution period were faster and better ($P < 0.001$, $P < 0.001$, $P < 0.001$, $P = 0.048$, $P = 0.010$, respectively).
P = 0.013, respectively). Thus, exposure to high PM$_{2.5}$ levels was associated with significantly reduced speed and degree of short- and medium-term LFR in patients who underwent lobectomy.

KEYWORDS
PM$_{2.5}$, pulmonary lobectomy, lung function, short-term, medium-term

Introduction

Lung cancer is the most lethal malignancy worldwide (1). Patients with surgically resectable lung cancer account for 40% of the total patient population with lung cancer (2). Most patients (70%) with resectable lung cancer undergo pulmonary lobectomy (3). Lobectomy is the surgical removal of the entire lobe of the lung (4), which is still the standard surgical procedure for patients with resectable lung cancer and some benign pulmonary diseases, although some patients with early stage lung cancer now receive sublobectomy (5, 6).

Long-term exposure to air pollution increases the risk of lung cancer and adversely affects lung function (7–12). Particulate matter with an aerodynamic diameter of 2.5 μm or less (PM$_{2.5}$) is one of the most harmful pollutants to lung health. Recently, several studies have shown that air pollution adversely affects lung function in children, adolescents, and adults (10, 13–15). Furthermore, there is growing epidemiological evidence that long-term exposure to air pollution, especially PM$_{2.5}$ and nitrogen dioxide (NO$_2$), in healthy people or in people with certain chronic lung diseases, is associated with lower forced lung capacity (FVC) and forced expiratory volume in 1 s (FEV1) (11, 12, 16, 17). The effects of air pollution on lung function may even appear during childhood (15).

Patients who undergo lobectomy lose 7–20% of their baseline lung function (18, 19). Because of intraoperative lung collapse and damage to the thoracic intercostal nerve, short- and medium-term lung function is gradually recovered after surgery (4). The concentration-response curve has shown a continued increase in the death rates associated with higher annual air pollutant concentrations (20), indicating that this is of particular concern in areas with higher air pollution levels, such as China, where PM$_{2.5}$ concentrations often exceed 50 μg/m$^3$ (20). A study in Shanghai, China, showed that long-term exposure to high levels of air pollution affects lung function in adults and patients with chronic airway disease (16). Identifying factors that alter the effects of air pollution on the respiratory system is necessary to prevent risks and to help develop interventions to protect vulnerable populations. Therefore, the impact of exposure to air pollution on short- and medium-term lung function recovery (LFR) in patients undergoing pulmonary lobectomy should be examined.

Patients who have undergone pulmonary lobectomy, constitute a large vulnerable group of individuals who will suffer permanent loss of baseline lung function after surgery (4, 6). The degree and speed of lung function recovery in the short- and medium-term are related to the quality of life and perioperative survival of patients (18, 19, 21). Previous studies mainly focused on healthy populations or populations with other diseases and did not explore the population that underwent pulmonary lobectomy (10, 11, 16, 17, 22). There is no evidence that the air environment has an impact of any degree on this group of people.

This is a longitudinal study that investigates the associations of a range of particle metrics with lung function in 526 patients who underwent pulmonary lobectomy in Guangzhou, China, from January 2018 to June 2021, when particulate matter was qualitatively and quantitatively different among periods with different pollution levels.

Methods

Study design and population

The current study is a longitudinal study that repeatedly measured each patient’s preoperative and postoperative lung function to assess the impact of changes in PM$_{2.5}$ concentrations, on the degree and speed of lung function recovery in the short- and medium-term after pulmonary lobectomy.

The data for PM$_{2.5}$, fine particulate matter with a diameter of <10μm (PM$_{10}$), sulfur dioxide (SO$_2$), nitrogen dioxide (NO$_2$), carbon monoxide (CO), and ozone (O$_3$) and the air quality index (AQI) in the study zone (Figure 1) were obtained from the data of six air monitoring stations located in the central district of Guangzhou city from January 2018 to June 2021. All data including temperature and relative humidity (RH) in the study zone were obtained from the China National Environmental Monitoring Center (http://www.cnemc.cn/en/).

The study zone is located in the central district of Guangzhou, a city in the Pearl River Delta, with a population of over six million. The area is densely populated and small. There is little difference in the annual average fine particulate matter...
air pollution at each monitoring station, while the monthly average air quality in the Pearl River Delta region fluctuates greatly due to the existence of a winter haze period, making the resident population in this region a natural model to study the effects of fine particulate matter air pollution on lung function in the short- and medium-term (23). Therefore, the geographical location of our study zone is suitable, and the six air monitoring stations included are representative for evaluating the air pollution characteristics of the area.

This study included patients who underwent video-assisted thoracoscopic (VATS) pulmonary lobectomy in the third affiliated hospital of Sun Yat-Sen University and General Hospital of Southern Theater Command from January 2018 to June 2021 (Figure 2). All patients were registered permanent residents living within four kilometers of the air monitoring stations. To facilitate follow-up statistics, data from the monitoring station with the closest linear distance to the patient’s residence were included in follow-up analysis. All patients underwent lung function tests before surgery, and at 3 months after surgery to observe short-term lung function recovery after surgery. Patients with slower lung function recovery in the third month after surgery were re-examined in the sixth month after surgery to observe medium-term lung function recovery after surgery. All patients were instructed on how to perform respiratory rehabilitation training and ensure reasonable nutritional intake before discharge. After discharge, irregular outpatient follow-ups were conducted to provide guidance to patients regarding postoperative rehabilitation.

None of the patients had received perioperative chemotherapy or radiotherapy, and their Eastern Cooperative Oncology Group performance status (ECOG PS) was $\leq 2$ before surgery and the first month after surgery. None of the patients in this study experienced serious postoperative complications. It is worth noting that all patients undergoing pulmonary lobectomy are routinely advised to quit smoking.

We assessed short-term lung function recovery after lobectomy in all 526 patients. The 3-month average PM$_{2.5}$ concentrations in each patient’s residential area were divided into three periods according to the PM$_{2.5}$ concentration levels. In addition, we assessed medium-term lung function recovery in 110 patients with unsatisfactory short-term lung function recovery after surgery and divided the 6-month average PM$_{2.5}$ concentration in each patient’s residential area into three periods according to the concentration level. The starting point for calculating the average PM$_{2.5}$ concentration was the time when patients were discharged from the hospital. Meanwhile, we collected environmental PM$_{2.5}$ concentrations from the nearest monitoring station during the same period.

The three periods comprised a regional mild pollution period ($\text{PM}_{2.5} < 25$ $\mu g/m^3$), a moderate pollution period ($25 \mu g/m^3 \leq \text{PM}_{2.5} < 35$ $\mu g/m^3$), and a severe pollution period ($35 \mu g/m^3 \leq \text{PM}_{2.5}$). These three time periods were created for three reasons: first, we performed multiple linear regression (MLR) analysis and confirmed that PM$_{2.5}$ was an independent risk factor affecting postoperative lung function recovery; second, most previous studies were conducted in areas

![FIGURE 1](image.png)

Map of Guangzhou (A) showing the location of the study zone (blue area) and that of six monitor stations in the study zone (B). The study zone is in the central city of Guangzhou with a population of over six million.
with typical annual PM$_{2.5}$ concentrations of $< 25 \, \mu g/m^3$; third, we took into consideration the secondary standard (35 $\mu g/m^3$) of the national ambient air quality standards in China (GB 3095-2012) (22, 24, 25).

**Lung function test**

Lung function tests were conducted by trained and certified technicians using electronic spirometers (ChestGraph HI-101, CHEST Ltd., Tokyo, Japan, or Quark PFT, COSMED Ltd., Rome, Italy). The tests were performed according to the testing protocol of European Respiratory Society/American Thoracic Society standards (ERS/ATS 2005) (26). In addition, we calculated the estimated predicted values of FVC, FEV1, and maximum expiratory flow at 50% vital capacity (MEF$_{50}$) (FVC%pred, FEV1%pred, and MEF$_{50}$%pred, respectively) based on the height, weight, age, and race of each patient (27). Based on preoperative lung function assessments by thoracic surgeons all patients could tolerate lobectomy (4). The following formula was used to evaluate the observed or expected loss of lung function after surgery.

\[
\text{Lung function loss} = \frac{\text{Preoperative lung function} - \text{postoperative lung function}}{\text{Preoperative lung function}} \times 100\% \tag{1}
\]

**Statistical analysis**

Continuous variables are presented as the mean ± standard deviation (SD). We assessed the data for normality using the Shapiro–Wilk test and for homogeneity of variances across period categories using the Bartlett's test for unequal variances (28, 29). Continuous variables in the three periods were assessed using the ANOVA test or Kruskal-Wallis test (30, 31). Categorical data were analyzed using the chi-squared test or Fisher's exact test. The correlation between continuous variables was assessed using Spearman's correlation analysis. Multicollinearity was analyzed by calculating variance inflation.
TABLE 1  Demographic characteristic of patients with pulmonary lobectomy during three periods.

| Variables                  | All patients | Mild pollution period | Moderate pollution period | Severe pollution period | P-value |
|----------------------------|--------------|-----------------------|---------------------------|-------------------------|---------|
|                            | N = 526     | Patients (N = 191)    | Patients (N = 189)        | Patients (N = 146)      |         |
| **Age (Mean ± SD) year**   | 61.38 ± 10.72 | 61.05 ± 11.16         | 60.81 ± 10.25             | 62.53 ± 10.69           | 0.220   |
| **Sex**                    |              |                       |                           |                         |         |
| Male                       | 292          | 100                   | 107                       | 85                      | 0.523   |
| Female                     | 234          | 91                    | 82                        | 61                      |         |
| **BMI (Mean ± SD) Kg/m²**  | 22.99 ± 3.05 | 22.17 ± 3.03          | 23.1 ± 3.05               | 23.2 ± 3.08             | 0.200   |
| **Smoking history**        |              |                       |                           |                         | 0.089   |
| Never                      | 304          | 102                   | 121                       | 81                      |         |
| Former or current          | 222          | 89                    | 68                        | 65                      |         |
| **Diagnosis**              |              |                       |                           |                         | 0.867   |
| Malignant                  | 463          | 170                   | 165                       | 128                     |         |
| Benign                     | 63           | 21                    | 24                        | 18                      |         |
| **Comorbidity**            |              |                       |                           |                         |         |
| COPD                       | 86           | 31                    | 36                        | 19                      | 0.334   |
| Hypertension               | 84           | 28                    | 30                        | 26                      | 0.736   |
| Diabetes                   | 73           | 25                    | 29                        | 19                      | 0.767   |
| **Resected_lobe**          |              |                       |                           |                         | 0.448   |
| Left lower                 | 93           | 34                    | 32                        | 27                      |         |
| Left upper                 | 143          | 48                    | 54                        | 41                      |         |
| Right lower                | 88           | 35                    | 37                        | 16                      |         |
| Right middle               | 39           | 18                    | 11                        | 10                      |         |
| Right upper                | 163          | 56                    | 55                        | 52                      |         |
| **Lung function**          |              |                       |                           |                         |         |
| FVC (Mean ± SD) L          | 2.92 ± 0.66  | 2.92 ± 0.62           | 2.88 ± 0.65               | 2.97 ± 0.72             | 0.650   |
| FEV1 (Mean ± SD) L         | 2.38 ± 0.52  | 2.4 ± 0.55            | 2.34 ± 0.51               | 2.41 ± 0.56             | 0.500   |
| MEF50 (Mean ± SD) L/S      | 3.1 ± 0.97   | 3.15 ± 1.03           | 3.06 ± 0.97               | 3.12 ± 0.87             | 0.470   |
| FVC %predicted (%)         | 91.49 ± 13.36| 91.17 ± 13.36         | 91.53 ± 13.69             | 91.86 ± 12.88           | 0.820   |
| FEV1 %predicted (%)        | 92.44 ± 12.90| 92.48 ± 12.97         | 91.81 ± 13.47             | 93.2 ± 12.07            | 0.620   |
| MEF50 %predicted (%)       | 82.65 ± 23.12| 82.77 ± 23.47         | 81.64 ± 23.88             | 83.81 ± 21.73           | 0.670   |
| **Medium-term (6 months)** |              |                       |                           |                         |         |
| Age (Mean ± SD) year       | 62.51 ± 10.12| 59.13 ± 10.11         | 62.76 ± 9.85              | 65.06 ± 10.36           | 0.130   |
| **Sex**                    |              |                       |                           |                         | 0.160   |
| Male                       | 74           | 14                    | 40                        | 20                      |         |
| Female                     | 36           | 9                     | 23                        | 4                       |         |
| BMI (Mean ± SD) Kg/m²      | 22.89 ± 2.88 | 22.96 ± 3.10          | 22.71 ± 2.75              | 23.29 ± 3.07            | 0.700   |
| **Smoking history**        |              |                       |                           |                         | 0.041   |
| Never                      | 70           | 16                    | 44                        | 10                      |         |
| Former or current          | 40           | 7                     | 19                        | 14                      |         |
| **Diagnosis**              |              |                       |                           |                         | 0.720   |
| Malignant                  | 101          | 23                    | 58                        | 21                      |         |
| Benign                     | 9            | 1                     | 5                         | 3                       |         |

(Continued)
| Variables | All patients | Mild pollution period | Moderate pollution period | Severe pollution period | P-value |
|-----------|--------------|-----------------------|--------------------------|------------------------|---------|
|           | PM$_{2.5}$ < 25 ug/m$^3$ | 25 ug/m$^3$ ≤ PM$_{2.5}$ < 35 ug/m$^3$ | 35 ug/m$^3$ ≤ PM$_{2.5}$ |             |         |
| Comorbidity |              |                       |                          |                        |         |
| COPD       | 11           | 3                     | 6                        | 2                      | 0.830   |
| Hypertension | 14           | 2                     | 10                       | 2                      | 0.580   |
| Diabetes   | 10           | 1                     | 7                        | 2                      | 0.820   |
| Resected lobe |              |                       |                          |                        | 0.160   |
| Left lower | 14           | 1                     | 9                        | 4                      |         |
| Left upper | 87           | 21                    | 50                       | 16                     |         |
| Right lower | 7            | 1                     | 3                        | 4                      |         |
| Right upper | 2            | 0                     | 1                        | 0                      |         |
| Lung function |              |                       |                          |                        |         |
| FVC (Mean ± SD) | 2.86 ± 0.72 | 2.73 ± 0.73          | 2.88 ± 0.73              | 2.95 ± 0.75            | 0.600   |
| FEV1 (Mean ± SD) | 2.34 ± 0.54 | 2.33 ± 0.60          | 2.37 ± 0.53              | 2.27 ± 0.55            | 0.600   |
| MEF50 (Mean ± SD) | 3.12 ± 0.89 | 3.29 ± 0.96          | 3.17 ± 0.89              | 2.83 ± 0.78            | 0.160   |
| FVC %predicted (%) | 93.17 ± 13.20 | 89.52 ± 12.86        | 93.71 ± 13.44            | 95.24 ± 12.72         | 0.300   |
| FEV1 %predicted (%) | 94.52 ± 11.98 | 93.38 ± 13.06        | 95.45 ± 12.45            | 93.16 ± 9.63          | 0.640   |
| MEF50 %predicted (%) | 84.52 ± 22.64 | 83.66 ± 24.19        | 87.42 ± 23.46            | 78.2 ± 17.92         | 0.230   |

SD, Standard deviation; COPD, Chronic obstructive pulmonary disease; BMI, Body mass index; FVC, Forced vital capacity; FEV1, Forced expiratory volume in 1 s; MEF50, Maximum expiratory flow at 50% vital capacity.

factor (VIF). Factors with VIF > 10 were judged as strong collinearity factors and adjusted in the subsequent MLR model.

The association between short-term lung function recovery/loss and exposure to fine particulate matter was assessed using the MLR model (32). Age, sex, BMI, smoking history, chronic obstructive pulmonary disease (COPD), hypertension, diabetes, location of the resected lobe, baseline lung function parameters, meteorological factors (3-month average temperature and relative humidity), and 3-month average concentrations of PM$_{2.5}$, PM$_{10}$, SO$_2$, NO$_2$, and CO were adjusted in all models. Similarly, the association between medium-term lung function recovery/loss and exposure to fine particulate matter was assessed using the MLR model (32). Age, sex, BMI, smoking history, COPD, hypertension, diabetes, location of the resected lobe, baseline lung function parameters, meteorological factors (6-month average temperature and relative humidity), and 6-month average concentrations of PM$_{2.5}$, PM$_{10}$, SO$_2$, NO$_2$, and CO were adjusted in all models.

In the analysis of short-term lung function recovery after surgery, the 3-month average PM$_{2.5}$ concentrations in each patient's residential area were divided into three periods according to the concentration level. Baseline data (age, sex, BMI, smoking history, diagnosis, comorbidities, location of the resected lobe, and lung function parameters) were statistically analyzed. The fine particulate matter (PM$_{2.5}$, PM$_{10}$, SO$_2$, NO$_2$, and CO) concentrations of the three periods were also statistically analyzed. Additionally, meteorological factors (temperature and relative humidity) of the three periods were also statistically analyzed. Similarly, in the analysis of medium-term lung function recovery after surgery, the 6-month average PM$_{2.5}$ concentrations in each patient's residential area were divided into three periods according to the concentration level. Baseline data (age, sex, BMI, smoking history, diagnosis, comorbidities, location of the resected lobe, and lung function parameters) were statistically analyzed. The fine particulate matter (PM$_{2.5}$, PM$_{10}$, SO$_2$, NO$_2$, and CO) concentrations of the three periods were also statistically analyzed. Additionally, meteorological factors (temperature and relative humidity) of the three periods were also statistically analyzed.

All statistical analyses were performed using R (version 3.6.1, R Foundation for Statistical Computing, http://cran.r-project.org/). A P-value of <0.05 was considered statistically significant for all results.

**Results**

**Study population and patient characteristics**

In total, 526 patients were included in this study (Table 1). All patients underwent at least two lung function tests, whereas
Average monthly air quality index (AQI) and exposure to PM$_{2.5}$, PM$_{10}$, SO$_2$, NO$_2$, CO, and O$_3$ in the study area from January 2018 to June 2021. Station A: Guangya middle school monitoring station; Station B: Guangzhou monitoring station; Station C: Luhu lake monitoring station; Station D: Guangzhou No. 5 middle school monitoring station; Station E: Guangdong business college monitoring station; Station F: Tiyu Xilu monitoring station. PM$_{2.5}$, fine particulate matter with a diameter of $<2.5\ \mu$m; PM$_{10}$, fine particulate matter with a diameter of $<10\ \mu$m; SO$_2$, sulfur dioxide; NO$_2$, nitrogen dioxide; CO, carbon monoxide; O$_3$, ozone.
110 patients underwent three lung function tests. Of the 526 patients who were assessed for short-term lung function recovery after surgery, 191 recovered in the mild pollution period, 189 in the moderate pollution period, and 146 in the severe pollution period. In the moderate pollution period, 63 in the moderate pollution period, and 24 in the severe pollution period. In the short-term lung function recovery group, there were no statistically significant differences in baseline data (age, sex, BMI, smoking history, diagnosis, comorbidities, location of the resected lobe, and lung function parameters) among the three periods. In the medium-term lung function recovery group, there were no statistically significant differences in baseline data (age, sex, BMI, diagnosis, comorbidities, location of resected lobe, and lung function parameters) among the three periods, but there were statistically significant differences in smoking history among patients at the three time points (P = 0.041).

Air pollution exposure and meteorological factors

From January 2018 to June 2022, except for the monthly average concentration of SO₂, the trends of the monthly average AQI and monthly average concentrations of PM₂.₅, PM₁₀, NO₂, CO, and O₃ of the six air monitoring stations in our study zone were similar (Figure 3). In addition, the monthly average AQI and monthly average concentrations of PM₂.₅, PM₁₀, NO₂, CO, and O₃ fluctuated significantly in the study zone (Figure 3). From January 2018 to June 2022, the average concentrations of PM₂.₅, PM₁₀, NO₂, CO, and O₃ in the study zone were 29.18 µg/m³, 51.05 µg/m³, 36.99 µg/m³, 43.95 µg/m³, and 43.95 µg/m³, respectively. The average AQI was 72.59 in the study zone (Table 2). In addition, the average temperature and relative humidity in study zone were 22.96°C and 79.79%, respectively (Table 2). In general, the average AQI and average concentrations of PM₂.₅, PM₁₀, NO₂, CO, and O₃ were the highest during the severe pollution period, followed by those in the moderate and mild pollution periods. In contrast, the average concentrations of O₃ were the highest in the mild pollution period, followed by those in the moderate and severe pollution periods (Table 2 and Supplementary material).

During the mild pollution period, the 3-month average concentration of PM₂.₅ was the lowest at 12 µg/m³. During the severe pollution period, the 3-month average concentration of PM₂.₅ was the highest at 52 µg/m³. In addition, during the mild pollution period, the 6-month average concentration of PM₂.₅ was the lowest at 15 µg/m³. During the severe pollution period, the 6-month average concentration of PM₂.₅ was the highest at 47 µg/m³. Hence, the AQI and fine particulate matter concentrations of the three periods differed greatly (Figure S1).
### TABLE 3 Impact factors of short-term lung function loss after pulmonary lobectomy.

| Variables         | FVC loss | FEV1 loss | MEF50 loss |
|-------------------|----------|-----------|------------|
|                   | Unadjusted | Adjusted | Unadjusted | Adjusted | Unadjusted | Adjusted |
|                   | P-value   | P-value*  | P-value    | P-value  | P-value    | P-value  |
| Age               | 0.024     | 0.035     | 0.069      | 0.124    | 0.154      | 0.314    |
| Sex               | 0.230     | 0.052     | 0.289      | 0.033    | 0.111      | <0.001   |
| M                 | Ref       | Ref       | Ref        | Ref      | Ref        | Ref      |
| F                 | Ref       | Ref       | Ref        | Ref      | Ref        | Ref      |
| BMI               | 0.882     | 0.816     | 0.747      | 0.75     | 0.766      | 0.873    |
| Smoking history   | Y         | 0.044     | 0.003      | 0.013    | 0.001      | 0.015    | <0.001   |
| N                 | Ref       | Ref       | Ref        | Ref      | Ref        | Ref      |
| COPD              | Y         | 0.145     | 0.035      | 0.019    | 0.106      | 0.002    | <0.001   |
| N                 | Ref       | Ref       | Ref        | Ref      | Ref        | Ref      |
| Hypertension      | Y         | 0.646     | 0.029      | 0.467    | 0.021      | 0.527    | 0.020    |
| N                 | Ref       | Ref       | Ref        | Ref      | Ref        | Ref      |
| Diabetes          | Y         | 0.775     | 0.144      | 0.148    | 0.001      | 0.094    | <0.001   |
| N                 | Ref       | Ref       | Ref        | Ref      | Ref        | Ref      |
| Resected lobe     | Left lower | Ref       | Ref        | Ref      | Ref        | Ref      |
| Left upper        | <0.001    | <0.001    | <0.001     | <0.001   | <0.001     | <0.001   |
| Right lower       | 0.134     | 0.223     | 0.084      | 0.110    | 0.954      | 0.734    |
| Right middle      | <0.001    | <0.001    | <0.001     | <0.001   | <0.001     | <0.001   |
| Right upper       | <0.001    | <0.001    | <0.001     | <0.001   | <0.001     | <0.001   |
| Baseline FVC      | 0.050     | 0.011     | 0.062      | 0.866    | 0.041      | 0.435    |
| Baseline FEV1     | 0.310     | 0.084     | 0.020      | 0.654    | 0.017      | 0.669    |
| Baseline MEF50    | 0.803     | 0.428     | 0.133      | 0.811    | 0.113      | 0.629    |
| PM2.5, 3M         | <0.001    | 0.041     | <0.001     | 0.014    | <0.001     | 0.016    |
| PM2.5, 3M         | <0.001    | 0.472     | <0.001     | 0.319    | <0.001     | 0.156    |
| SO2, 3M          | 0.072     | 0.497     | 0.154      | 0.121    | 0.081      | 0.039    |
| NO2, 3M          | <0.001    | 0.420     | <0.001     | 0.404    | <0.001     | 0.725    |
| CO, 3M           | <0.001    | 0.037     | <0.001     | 0.598    | <0.001     | 0.537    |
| Temperature       | 0.895     | 0.102     | 0.238      | 0.918    | 0.203      | 0.748    |
| Relative humidity | 0.225     | 0.103     | 0.096      | 0.187    | 0.18       | 0.528    |

*Adjusted P-values were obtained by adjusting for confounding factors (Age, sex, BMI, smoking history, COPD, hypertension, diabetes, location of resected lobe, baseline lung function parameters, and 3-month average concentration of PM2.5, PM10, NO2, and CO) through multiple linear regression models.

FVC, Forced vital capacity; FEV1, Forced expiratory volume in 1 s; MEF50, Maximum expiratory flow at 50% vital capacity; BMI, Body mass index; COPD, Chronic obstructive pulmonary disease; PM2.5, Fine particulate matter with a diameter <2.5 µm; PM10, Fine particulate matter with a diameter <10 µm; SO2, Sulfur dioxide; NO2, Nitrogen dioxide; CO, Carbon monoxide; 3M, 3-month average.

---

**Associations of PM2.5 and its constituents with lung function**

Table 3 shows that the MLR model confirmed that the concentration of PM2.5 was an independent risk factor affecting short-term FVC, FEV1, and MEF50 recovery (adjusted \(P = 0.003\)). The largest difference between the three periods was in the average concentration of PM2.5 (Figure S1). Figure 4 shows only a small loss of short-term lung function after surgery in patients who underwent lobectomy during the mild pollution period, indicating that patients had faster and better lung...
TABLE 4 Impact factors of medium-term lung function loss after pulmonary lobectomy.

| Variables          | FVC loss | FEV1 loss | MEF<sub>50</sub> loss |
|--------------------|----------|-----------|-----------------------|
|                    | Unadjusted | Adjusted  | Unadjusted | Adjusted  | Unadjusted | Adjusted  |
|                    | P-value   | P-value*  | P-value   | P-value   | P-value   | P-value   |
| Age                | 0.684     | 0.545     | 0.856     | 0.027     | 0.281     | 0.414     |
| Sex                |           |           |           |           |           |           |
| M                  | 0.484     | 0.577     | 0.629     | 0.602     | 0.656     | 0.740     |
| F                  | Ref       | Ref       | Ref       | Ref       | Ref       | Ref       |
| BMI                | 0.761     | 0.263     | 0.686     | 0.204     | 0.948     | 0.729     |
| Smoking history    |           |           |           |           |           |           |
| Y                  | 0.136     | 0.561     | 0.087     | 0.344     | 0.565     | 0.397     |
| N                  | Ref       | Ref       | Ref       | Ref       | Ref       | Ref       |
| COPD               |           |           |           |           |           |           |
| Y                  | 0.029     | 0.111     | 0.357     | 0.543     | 0.084     | 0.355     |
| N                  | Ref       | Ref       | Ref       | Ref       | Ref       | Ref       |
| Hypertension       |           |           |           |           |           |           |
| Y                  | 0.890     | 0.101     | 0.697     | 0.270     | 0.914     | 0.356     |
| N                  | Ref       | Ref       | Ref       | Ref       | Ref       | Ref       |
| Diabetes           |           |           |           |           |           |           |
| Y                  | 0.428     | 0.377     | 0.009     | 0.083     | 0.337     | 0.851     |
| N                  | Ref       | Ref       | Ref       | Ref       | Ref       | Ref       |
| Resected lobe      |           |           |           |           |           |           |
| Left lower         | Ref       | Ref       | Ref       | Ref       | Ref       | Ref       |
| Left upper         | <0.001    | <0.001    | <0.001    | <0.001    | 0.02      | 0.003     |
| Right lower        | 0.717     | 0.529     | 0.204     | 0.130     | 0.111     | 0.060     |
| Right upper        | 0.140     | 0.047     | 0.019     | 0.008     | 0.495     | 0.342     |
| Baseline FVC       | 0.239     | 0.397     | 0.518     | 0.660     | 0.094     | 0.782     |
| Baseline FEV1      | 0.071     | 0.461     | 0.168     | 0.877     | 0.125     | 0.845     |
| Baseline MEF<sub>50</sub> | 0.633 | 0.209 | 0.572 | 0.602 | 0.621 | 0.840 |
| PM<sub>2.5</sub> -6M | 0.160 | 0.118 | 0.288 | 0.361 | 0.003 | 0.046 |
| PM<sub>10</sub> -6M | 0.199 | 0.677 | 0.283 | 0.861 | 0.006 | 0.854 |
| SO<sub>2</sub> -6M | 0.746 | 0.134 | 0.286 | 0.573 | 0.207 | 0.873 |
| NO<sub>2</sub> -6M | 0.085 | 0.545 | 0.231 | 0.751 | 0.090 | 0.337 |
| CO -6M             | 0.260 | 0.837 | 0.374 | 0.154 | 0.111 | 0.886 |
| Temperature        | 0.464 | 0.606 | 0.989 | 0.557 | 0.739 | 0.694 |
| Relative humidity  | 0.457 | 0.320 | 0.389 | 0.383 | 0.936 | 0.624 |

*Adjusted P-values were obtained by adjusting for confounding factors (Age, sex, height, weight, BMI, smoking history, COPD, hypertension, diabetes, location of resected lobe, baseline lung function parameters, 6-month average concentration of PM<sub>2.5</sub>, PM<sub>10</sub>, NO<sub>2</sub>, NO<sub>2</sub>, and CO) through multiple linear regression models.

FVC, Forced vital capacity; FEV1, Forced expiratory volume in 1 s; MEF<sub>50</sub>, Maximum expiratory flow at 50% vital capacity; BMI, Body mass index; COPD, Chronic obstructive pulmonary disease; PM<sub>2.5</sub>, Fine particulate matter with a diameter <2.5 µm; PM<sub>10</sub>, Fine particulate matter with a diameter <10 µm; SO<sub>2</sub>, Sulfur dioxide; NO<sub>2</sub>, Nitrogen dioxide; CO, Carbon monoxide; 6M, 6-month average.

function (FVC, FEV1, and MEF<sub>50</sub>) recovery after surgery during this period (P < 0.001, P < 0.001, P < 0.001, respectively). In addition, we assessed the medium-term recovery of lung function in patients with unsatisfactory short-term recovery of lung function after surgery. Figure 5 shows that medium-term lung function (FVC, FEV1, and MEF<sub>50</sub>) recovery in patients during the mild pollution period was better than that in patients during the moderate and severe pollution periods (P = 0.048, P = 0.010, P = 0.013, respectively). However, the medium-term recovery of lung function in patients was not statistically different during the moderate and severe pollution periods.

Discussion

Ambient air pollution increases morbidity and mortality associated with respiratory diseases (20, 25). Long-term
exposure to ambient air pollution can impair lung function in people of all ages (14–16). In this longitudinal study of patients with pulmonary lobectomy from Guangzhou, China, we found that the three- and 6-month average concentrations of PM$_{2.5}$ were significantly associated with higher FVC loss, FEV1 loss, and MEF$_{50}$ loss, indicating that air pollution-related lung function was impaired in the short- and medium-term.

In contrast to most studies, a special population of patients with pulmonary lobectomy was included in the current study to explore the relationship between lung function and PM$_{2.5}$ concentration. Given the high incidence of lung cancer, a large patient population has the opportunity to undergo pulmonary lobectomy. Previous studies on the factors influencing lung function recovery after pulmonary lobectomy mostly focused on medical perspectives, such as analysis of physical fitness and postoperative complications (18, 19, 21). However, it is unclear whether the external environment influences lung function recovery and to what extent. Few clinicians have paid attention to this critical issue in clinical practice. In fact, many previous studies have confirmed that even short-term exposure to PM$_{2.5}$ can impair lung function in healthy people and patients with COPD (33–36). Furthermore, a few previous studies have confirmed that long-term exposure to PM$_{2.5}$ could impair small airway function (12, 37, 38). The MEF$_{50}$ is an important indicator of small airway function. In this study, we observed that exposure to ambient PM$_{2.5}$ generally had a stronger association with MEF$_{50}$ than with FVC and FEV1. This finding suggests that short- and medium-term exposure to PM$_{2.5}$ may have more serious effects on small airway function than on large airway function in this vulnerable population.

The degree of lung function loss or recovery in patients undergoing pulmonary lobectomy is related to the location of the resected lobe (18, 19). Patients who underwent right middle lobectomy lost approximately 7% of their FVC and 12% of their FEV1 (18). However, patients with left upper lobectomy lost approximately 17% of their FVC and 18% of their FEV1 (18). Our MLR model also showed that the location of the resected lobe was an independent risk factor for loss of lung function (Tables 3, 4). In addition, short-term lung function recovery was worse in current/former smokers and in men. Previous studies have shown negative associations between FVC and FVC%pred in never-smokers and women.
Medium-term (6 months) lung function changes in patients with pulmonary lobectomy during the three periods. (A) Forced vital capacity (FVC) change after pulmonary lobectomy during the three periods. (B) Forced expiratory volume in 1 s (FEV1) change after pulmonary lobectomy during the three periods. (C) Maximum expiratory flow at 50% vital capacity (MEF50) change after pulmonary lobectomy during the three periods. (D) Overview of lung function loss after pulmonary lobectomy during the three periods. The three periods are periods with mild, moderate, and severe pollution.

Furthermore, comorbidities can affect the recovery of short-term postoperative lung function, which may be due to the relatively poor physical fitness of these patients (18). Due to the degree of postoperative pain and the possible effects of respiratory rehabilitation training on lung function recovery, a conventional outpatient follow-up was conducted in the first month after surgery to evaluate patient recovery. Most patients can undergo respiratory rehabilitation training. Patients with poor recovery were irregularly followed up to assist them with respiratory rehabilitation training. Finally, chest CT reexamination of all patients 3 months after surgery indicated good pulmonary re-expansion.

Different from other regions, the monthly average concentration of PM$_{2.5}$ in the Pearl River Delta region fluctuates greatly due to the existence of a winter haze period (23). In our study zone, the 3-month average concentration of PM$_{2.5}$ was 12 $\mu$g/m$^3$ at the lowest level and 52 $\mu$g/m$^3$ at the highest level, and the 6-month average concentration of PM$_{2.5}$ was 15 $\mu$g/m$^3$ at the lowest level and 47 $\mu$g/m$^3$ at the highest level. In addition, several studies used a spatiotemporal model based on high spatial resolution satellite data to estimate the PM$_{2.5}$ exposure for each participant’s address, which were more precise and reliable than studies based on monitoring stations. Furthermore, the regions investigated in these studies are large and geographically complex, the study span is long, and a high-precision spatiotemporal model is necessary. However, our study zone is in the central district of Guangzhou city, with a narrow geographical area and large population. This is a typical metropolitan residential area without large factories and forests, and its geographical environment is relatively simple. Therefore, data from air monitoring stations in the area are appropriate. In this area, there is no significant spatial difference in the monthly average PM$_{2.5}$ exposure level, but there is a significant time difference, which becomes a natural model of air environment change in the short- and medium-term.

This study had several important strengths. First, it further supports the first evidence of negative associations between short- and medium-term PM$_{2.5}$ exposure and lung function in areas with low to high levels of air pollution in a special population. Second, all patients underwent at least two lung function tests, which enabled longitudinal analysis. Third, unlike other studies based on healthy participants, our study population comprised postoperative patients and multiple follow-up visits with detailed data. In the MLR model, we adjusted for potential confounders and reduced the bias. Finally, to the best of our knowledge, this study is the first to investigate
the relationship between PM$_{2.5}$ concentration and the speed and degree of short- and medium-term lung function recovery in patients with pulmonary lobectomy.

Our study had several limitations. First, not every patient underwent lung function tests at the sixth month after surgery, and only 20% of patients were included in the assessment of the relationship between PM$_{2.5}$ concentration and medium-term lung function recovery. Even in the case of poor short-term recovery of lung function, the lung function of patients during mild pollution periods was significantly recovered compared to that of patients during moderate and severe pollution periods. Although there was no statistical difference in lung function recovery/loss between patients during moderate pollution periods and severe pollution periods. Although there was no statistical difference in lung function recovery between patients during moderate pollution periods and severe pollution periods in the medium-term lung function assessment, we still observed a different trend between the two periods, which may become statistically significant in larger populations. Second, although we adjusted for many personal and environmental factors, there is still uncertainty in estimating individual exposure due to unmeasured contaminant levels at the micro-environmental level. In addition, postoperative patients may be in an indoor environment for a relatively long time, and the effect of the air pollution level on the degree and speed of lung function recovery in patients remains to be further studied. Third, when evaluating medium-term lung function recovery, we noticed that the short-term lung function evaluations of some patients were conducted during mild or severe pollution periods, whereas the medium-term lung function evaluations of these patients were conducted during moderate pollution periods. Owing to the small number of patients included in the medium-term lung function evaluation, it is difficult to obtain robust statistical analysis results regarding differences in lung function recovery between patients in mild and moderate pollution periods and between patients in severe and moderate pollution periods. Finally, the lung function recovery of patients after lobectomy in areas with low PM$_{2.5}$ concentration in the Pearl River Delta was not included in our study. In our study zone, the 3-month average concentration of PM$_{2.5}$ was 19.75 $\mu$g/m$^3$, and the 6-month average concentration of PM$_{2.5}$ was 21 $\mu$g/m$^3$, even in the mild pollution period. This is far higher than the concentration of PM$_{2.5}$ recommended by the World Health Organization Global Air Quality Guidelines (WHO AQG) (39). We will further include the data of short- and medium-term lung function recovery in patients with pulmonary lobectomy in areas with low PM$_{2.5}$ concentration, to explore the impact of low PM$_{2.5}$ exposure on this particular population.

Conclusions

Our findings suggest that exposure to high levels of ambient PM$_{2.5}$ are associated with significantly reduced speed and degree of short- and medium-term lung function recovery in Chinese patients undergoing pulmonary lobectomy. The effects were modified by age, sex, BMI, smoking history, COPD, hypertension, diabetes, location of the resected lobe, baseline lung function parameters, and monthly or monthly average concentrations of PM$_{10}$, SO$_2$, NO$_2$, and CO, allowing for the identification of related risk factors. Further research is needed to replicate these findings in populations exposed to a wider range of pollutant concentrations, and to make recommendations for reducing particulate matter air pollution exposure during recovery in this vulnerable population. However, a small indoor air purifier may be helpful for lung function recovery in patients undergoing pulmonary lobectomy.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committee of Medical Scientific Research Foundation of Guangdong Province, China (Ethics Clearance:2021[073]). The patients/participants provided their written informed consent to participate in this study.

Author contributions

Conception and design: XWY, JH, and YX. Development of methodology and administrative, technical, or material support: XWY, YTL, JH, YX, XNW, YMC, and ZQH. Acquisition of data: XY, YTL, YX, and HH. Analysis and interpretation of data: XWY, YTL, JH, YX, XNW, and HH. Writing, review, and revision of the manuscript: XWY, YTL, JH, YX, XNW, YMC, ZQH, and HH. Study supervision: XY, YTL, JH, and XNW. Other (algorithm and software development): XY, YTL, and XNW. All authors contributed to the article and approved the submitted version.

Funding

This research was supported by the National Natural Science Foundation of China (41801074 and 41871085), Medical Scientific Research Foundation of Guangdong Province, China (No. A2022142), Research and Practice of Education and Teaching Reform in Guangdong Province (GDGZ19Y066), Innovative Project of Ordinary University in Guangdong Province (2019GKTSCX067), and Youth Innovative
Acknowledgments

We would like to thank Editage (www.editage.cn) for English Language Editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.1022199/full#supplementary-material
26. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J.* (2005) 26:319–38. doi: 10.1183/09031936.05.00834805

27. Hankinson JL, Odenacrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. *Am J Respir Crit Care Med.* (1999) 159:179–87. doi: 10.1164/ajrccm.159.1.9712108

28. Shapiro SS, Wilk MB. An analysis of variance test for normality (Complete Samples). *Biometrika.* (1965) 52:591–611. doi: 10.1093/biomet/52.3-4.591

29. Bartlett MS. Properties of sufficiency and statistical tests. *Proc R Soc London A Math Phy Sci.* (1937) 160:268–82. doi: 10.1098/rspa.1937.0109

30. Amster SJ. Beyond ANOVA, basics of applied statistics. *Technometrics.* (1987) 29:387. doi: 10.1080/00401706.1987.10488261

31. Corder GW, Foreman DJ. *Nonparametric Statistics for Non-Statisticians.* Hoboken, NJ: Wiley–Blackwell (2009).

32. Freedman D. *Statistical Models: Theory and Practice.* Cambridge: Cambridge University Press (2005).

33. Strassmann A, de Hoogh K, Röösli M, Haile SR, Turk A, Bopp M, et al. NO2 and PM2.5 exposures and lung function in swiss adults: estimated effects of short-term exposures and long-term exposures with and without adjustment for short-term deviations. *Environ Health Perspect.* (2021) 129:17009. doi: 10.1289/EHP P7529

34. Duan R, Niu H, Yu T, Huang K, Cui H, Chen C, et al. Adverse effects of short-term personal exposure to fine particulate matter on the lung function of patients with chronic obstructive pulmonary disease and asthma: a longitudinal panel study in Beijing, China. *Environ Sci Pollut Res Int.* (2021) 28:47463–73. doi: 10.1007/s11356-021-13811-y

35. Ye Z, Wang B, Mu G, Zhou Y, Qiu W, Yang S, et al. Short-term effects of real-time individual fine particulate matter exposure on lung function: a panel study in Zhubai, China. *Environ Sci Pollut Res Int.* (2021) 28:65349–9. doi: 10.1007/s11356-021-15246-x

36. Wu S, Ni Y, Li H, Pan L, Yang D, Baccarelli AA, et al. Short-term exposure to high ambient air pollution increases airway inflammation and respiratory symptoms in chronic obstructive pulmonary disease patients in Beijing, China. *Environ Int.* (2016) 94:76–82. doi: 10.1016/j.envint.2016.05.004

37. Hwang BE, Chen YH, Lin YT, Wu XT, Leo Lee Y. Relationship between exposure to fine particulates and ozone and reduced lung function in children. *Environ Res.* (2015) 137:382–90. doi: 10.1016/j.envres.2015.01.009

38. Ofstedal B, Brunekreef B, Nystad W, Madsen C, Walker SE, Naftad P. Residential outdoor air pollution and lung function in schoolchildren. *Epidemiology.* (2008) 19:129–37. doi: 10.1097/EDE.0b013e3181c50827

39. World Health Organisation. *WHO Global Air Quality Guidelines: Particulate Matter (PM2.5 and PM10), Ozone, Nitrogen Dioxide, Sulfur Dioxide and Carbon Monoxide.* Geneva: World Health Organization (2021).